Is NAMS a Buy? What to Consider in 2026
Short answer
The bull case for NAMS (NAMS) rests on Obicetrapib approval path: Obicetrapib has posted positive pivotal Phase 3 data (LDL-C reductions of roughly 33% as monotherapy and about 49% combined with ezetimibe in reported studies), which underpins regulatory filings in the US and Europe. Revenue (TTM) is ~$22.6M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The company is pre-commercial with negligible revenue, so the valuation depends on obicetrapib being approved and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. Whether NAMS is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company headquartered in Naarden, the Netherlands, and listed on Nasdaq under the ticker NAMS. Its lead candidate is obicetrapib, an oral, once-daily, low-dose CETP inhibitor being developed as a non-statin option (alone or as a fixed-dose combination with ezetimibe) to lower LDL cholesterol in patients who are not reaching targets on existing therapy. The company reported positive topline data from pivotal Phase 3 trials including BROADWAY, BROOKLYN and TANDEM, and is running the large PREVAIL cardiovascular outcomes trial; ex-US rights are partnered with the Menarini Group, and an earlier-stage Phase 2a program explores obicetrapib in Alzheimer's disease. The investment picture is a classic late-stage biotech setup. As of the Q1 2026 report (reported May 2026), NewAmsterdam was still pre-commercial with only modest supply revenue (about $3.0 million in the quarter) and a net loss of roughly $48 million, but it held about $707 million in cash and marketable securities, giving it a multi-year runway to fund trials and a potential US launch. The market capitalization of around $4.4 billion prices in substantial commercial success for obicetrapib, so the stock behaves like an option on regulatory approval and the PREVAIL outcomes readout rather than on current financials.
What's the case for buying NAMS?
1. Obicetrapib approval path
Obicetrapib has posted positive pivotal Phase 3 data (LDL-C reductions of roughly 33% as monotherapy and about 49% combined with ezetimibe in reported studies), which underpins regulatory filings in the US and Europe. Approval as an oral, non-statin add-on would open a large addressable population of statin-treated patients who remain above LDL targets.
2. Oral, once-daily convenience versus injectables
The competitive pitch is a pill rather than an injection. Leading potent LDL-lowering drugs such as PCSK9 inhibitors are injectables, so an effective oral option could appeal to patients and prescribers who prefer a tablet, potentially widening use in primary care.
3. Deep cash runway and Menarini partnership
About $707 million in cash and marketable securities (as of Q1 2026) funds the ongoing PREVAIL outcomes trial and launch preparation without immediate financing pressure. The Menarini Group partnership provides ex-US commercialization reach and some non-dilutive economics.
4. Cardiovascular outcomes optionality
The PREVAIL cardiovascular outcomes trial could, if positive, extend the label from LDL lowering to demonstrated event reduction, which historically drives payer coverage and broader adoption. A favorable outcomes readout would be the single largest potential value inflection.
What are the risks to NAMS?
The company is pre-commercial with negligible revenue, so the valuation depends on obicetrapib being approved and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. CETP inhibitors as a class have a difficult history, with several prior candidates from large pharma failing in outcomes trials, which keeps skepticism elevated. Concentration is extreme because essentially all value sits in one molecule. Ongoing losses mean future capital raises and shareholder dilution are possible despite the current cash cushion. Commercial risk is real even after approval, given entrenched generics, injectable PCSK9 competitors, and payer access hurdles.
How is NAMS valued? (as of MAY 2026)
Snapshot for NAMS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$22.6M
- Revenue (Q1 2026): ~$3.0M
- Net loss (Q1 2026): ~$48.4M
- EPS (Q1 2026): ~-$0.40
- Cash & marketable securities: ~$707M
- Market cap: ~$4.4B
The revenue base is tiny and consists mainly of product supply under the Menarini agreement, so traditional multiples are not meaningful. The stock trades as a clinical-stage bet where the roughly $4.4 billion market cap reflects expectations for obicetrapib rather than current sales. The large cash balance relative to the quarterly burn is the reason the company can fund trials and a potential launch without near-term financing.
How do you decide if NAMS is a buy?
Rather than asking whether NAMS is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold NAMS indirectly through an index or sector ETF before adding more.
For the full picture, see the NAMS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about NAMS against your real portfolio and see your actual exposure before deciding.
The bottom line on NAMS
The bottom line: NAMS's story right now is Obicetrapib approval path, with revenue (ttm) at ~$22.6M. If you believe that narrative continues, the call is about sizing NAMS sensibly and checking overlap with what you own; if you doubt it (the risk: the company is pre-commercial with negligible revenue, so the valuation depends on obicetrapib being approved and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around NAMS with Walnut
Use NAMS as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is NAMS a good stock to buy right now?
+
The case for NAMS right now is Obicetrapib approval path, with revenue (ttm) at ~$22.6M. If you believe that thesis holds, NAMS is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the company is pre-commercial with negligible revenue, so the valuation depends on obicetrapib being approved and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does NAMS do?
+
NewAmsterdam Pharma Company N.V.
What are the main risks of NAMS?
+
The company is pre-commercial with negligible revenue, so the valuation depends on obicetrapib being approved and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. CETP inhibitors as a class have a difficult history, with several prior candidates from large pharma failing in outcomes trials, which keeps skepticism elevated. Concentration is extreme because essentially all value sits in one molecule. Ongoing losses mean future capital raises and shareholder dilution are possible despite the current cash cushion. Commercial risk is real even after approval, given entrenched generics, injectable PCSK9 competitors, and payer access hurdles.
What does NewAmsterdam Pharma (NAMS) do?
+
It is a late-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for lowering LDL cholesterol in patients with cardiovascular disease and inherited high-cholesterol conditions. It is pre-commercial, meaning it does not yet sell an approved drug at scale.
What is obicetrapib?
+
Obicetrapib is an oral, once-daily, low-dose CETP inhibitor designed to lower LDL cholesterol, developed alone or as a fixed-dose combination with ezetimibe. In reported Phase 3 trials it lowered LDL-C by roughly 33% as monotherapy and about 49% in combination with ezetimibe.
Is NAMS profitable?
+
No. As of the Q1 2026 report (May 2026) the company had only about $3.0 million in quarterly revenue and posted a net loss of roughly $48.4 million. Like most clinical-stage biopharma, it spends heavily on trials while awaiting approval.
How much cash does NewAmsterdam have?
+
The company reported about $707 million in cash and marketable securities as of Q1 2026 (May 2026). That balance is meant to fund the PREVAIL outcomes trial and launch preparation, giving it a multi-year runway relative to its current burn rate.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell NAMS; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.